The aim of the present study was to investigate whether increasing the bosentan dosing frequency from 2 mg kg -1 twice daily (b.i.d.) to 2 mg kg -1 three times daily (t.i.d.) in children with pulmonary arterial hypertension (PAH) (from ≥3 months to <12 years of age) would increase exposure.
CONCLUSIONS
There appeared to be no clinically relevant difference in exposure to bosentan, or in safety, when increasing the frequency of bosentan dosing from b.i.d. to t.i.d. Therefore, the present study provides no indication that the dosing recommendation should be changed, and 2 mg kg -1 b.i.d. remains the recommended dosing regimen for bosentan in paediatric PAH patients.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• In paediatric pulmonary arterial hypertension patients: ◯ Bosentan exposure following 2 mg kg -1 twice-daily (b.i.d.) dosing is approximately half that observed in adults with bosentan 125 mg b.i.d., whereas the efficacy seems to be similar. ◯ Increasing the dose to 4 mg kg -1 b.i.d. does not increase exposure.
◯ Bosentan has been shown to be well tolerated at both doses.
WHAT THIS STUDY ADDS
• The present study used a new bosentan dosing regimen, 2 mg kg -1 t.i.d., to investigate whether exposure could be increased in paediatric pulmonary arterial hypertension patients.
• The study also provided the first information on bosentan safety and pharmacokinetics in patients below 2 years of age.
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Introduction
Pulmonary arterial hypertension (PAH) is a progressive disease caused by proliferation and remodelling of the pulmonary vasculature, resulting in right ventricular failure and death [3, 4] . With regard to definition, pathophysiology, symptoms and response to PAH-specific therapies, there are important similarities between PAH in children and in adults [5] .
The use of PAH-specific therapies in paediatric patients is generally based on evidence from randomized controlled trials in adults. Data to support their use in children are limited mainly to uncontrolled studies and clinical experience [6] [7] [8] [9] [10] . There is also a general lack of information with regard to safety and optimal dosing strategies in paediatric PAH patients [7] . The European Medicines Agency (EMA) guidelines for the conduct of paediatric PAH studies require comprehensive pharmacokinetic (PK) data and longterm safety data to be provided [7] . Therefore, there is a clear need for long-term trials in paediatric PAH, with an emphasis on the collection of both PK and safety data, as it is difficult to extrapolate from adult studies [11] .
Bosentan is an oral dual endothelin receptor antagonist (ERA) that is approved for the treatment of PAH [12] . Studies have been conducted to support the effectiveness of bosentan using haemodynamic variables in adult [13] [14] [15] [16] and paediatric patients [9] . Similar haemodynamic improvements were shown in both populations after administration of the film-coated (adult) tablet formulation [9, [13] [14] [15] [16] . In the Bosentan Randomised Trial of Endothelin Antagonist Therapy-3 (BREATHE-3), clinically relevant improvements from baseline in the exploratory endpoints mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) index were observed after 12 weeks of treatment, even though bosentan plasma concentrations in paediatric patients did not reach those previously observed in adult PAH patients (approximately 50% lower) [8, 9, 17] . Several observational studies have also indicated that bosentan may be effective in the treatment of paediatric PAH [18] [19] [20] [21] . One study demonstrated that bosentan improved or maintained World Health Organization functional class (WHO FC) in 90% of patients over a median treatment duration of 14 months; decreases in mPAP and PVR were also observed [18] .
In the Paediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion (FUTURE-1) open-label, uncontrolled study, an oral, dispersible paediatric formulation of bosentan with a quadrisecting score line was investigated, which provided more flexible dosing and increased acceptance for paediatric patients [8] . A systemic exposure plateau was observed at a dose of 2 mg kg -1 twice daily (b.i.d.) in paediatric patients, with administration of bosentan at 4 mg kg -1 b.i.d. not resulting in higher plasma concentrations. As a result, the level of exposure to bosentan observed in adult PAH patients could not be reached in paediatric patients with b.i.d. dosing [8] . Nevertheless, observations in bosentan-naïve patients suggested a beneficial therapeutic effect following initiation of bosentan [8] . FUTURE-2, an open-label, uncontrolled extension of FUTURE-1 in which patients were allowed additional PAH-specific therapy in the case of PAH worsening, demonstrated an improvement in different efficacy parameters over long-term treatment [6] . The paediatric formulation of bosentan was well-tolerated in both FUTURE studies [6, 8] Randomized treatment assignment was centralized via an interactive voice/web response system in order to avoid investigator bias in the allocation of treatment. Patients who prematurely discontinued study treatment had to complete an end-of-study (EOS) assessment. Patients completing the study had the option of participation in a 1-year follow-up extension study. Those patients who did not enter the 1-year follow-up extension had a 60-day post-treatment follow-up of serious adverse events (SAEs) and deaths.
Patients
The study population included male and female PAH patients (≥3 months to <12 years of age) with idiopathic PAH (IPAH), heritable PAH (HPAH) or associated PAH (APAH) persisting after complete repair of a congenital heart defect, or PAHcongenital heart disease (CHD) associated with systemic-topulmonary shunts or Eisenmenger syndrome. Patients with small defects and co-incidental APAH-CHD were also permitted to enrol in the study. Patients were in WHO FC I-III and diagnosed by right heart catheterization (RHC). Baseline PAH therapy (calcium channel blocker, bosentan, PDE-5 inhibitor, prostanoid), if present, had to be stable for at least 3 months prior to screening. Exclusion criteria included aspartate transaminase (AST) or alanine aminotransferase (ALT) levels >1.5 times the upper limit of normal range, moderate to severe hepatic impairment and haemoglobin and/or haematocrit levels <75% of the lower limit of normal range. Patients who required additional or an increased dose of PAH-specific therapy had to discontinue the study, with the option of joining the 1-year follow-up extension study. The protocol was approved by the Independent Ethics Committee or Institutional Review Board at each participating centre (Table S1 ) and the study was performed in accordance with the principles of the Declaration of Helsinki and within the regulations for each country. Written informed consent was obtained from every child's parents or legal representatives (and assent was obtained from each child if applicable) prior to any study procedure.
Outcome measures
The main PK endpoint was defined as the daily exposure to bosentan -i.e., the area under the concentration-time curve (AUC) over a period of 24 h corrected to the 2 mg kg -1 target dose (AUC 0-24C ), for b.i.d. or t.i.d. dosing (refer to PK and statistical analyses section for details). Dose-corrected values were used as the smallest dose unit was 8 mg (a quarter of a tablet), so it was not possible to achieve the exact target dose in all patients. Other PK endpoints were the maximum plasma concentration corrected to the 2 mg kg -1 dose (C maxC ) of bosentan, time to reach the maximum plasma concentration (t max ) of bosentan, and metabolite to parent AUC 0-24C ratio for the metabolites Ro 47-8634, Ro 48-5033, and Ro 64-1056. The PK of the three metabolites was assessed in order to understand whether a potential difference in exposure to bosentan could be explained by the activity of the cytochrome P450 (CYP)3A4 and/or CYP2C9 enzymes responsible for the formation of these metabolites. Safety endpoints included occurrence of treatment-emergent AEs, SAEs, AEs leading to treatment discontinuation, death, laboratory abnormalities, change from baseline in vital signs and 12-lead electrocardiogram (ECG), and growth.
Trial procedures and analytical methods
Patient characteristics and demographic data were collected at baseline. PK assessments were performed at week 4, after at least 2 weeks of stable study treatment. Blood samples were collected into ethylene diamine tetra-acetic acid-containing tubes by venepuncture or from an indwelling catheter in an arm vein. For the 2 mg kg
were collected immediately before administration of the study medication dose (predose), and at 0.5, 1, 3, 7.5 and 12 h postdose. For the 2 mg kg -1 t.i.d. dosing regimen, samples were collected predose and at 0.5, 1, 3, 5 and 8 h postdose. Concentrations of bosentan and its metabolites in plasma were determined as previously described [22] or by using liquid chromatography-tandem-mass spectrometry following protein precipitation with methanol. The lower limit of quantification for bosentan varied between 1.00 ng ml -1 and 2.00 ng ml -1 , and for Ro 47-8634, Ro 48-5033 and Ro 64-1056 it was 2.00 ng ml -1 . The day-to-day precision for both methods varied between 1.2% and 15.1% for bosentan and its metabolites, and accuracy varied between 85.1% and 112.9%. Dried blood spot samples were also collected and compared with the plasma samples [23] . Safety and tolerability were evaluated by monitoring safety variables, including laboratory abnormalities, AEs, SAEs, death, vital signs, 12-lead ECG and growth.
PK and statistical analyses
The sample size was based on the expectation that recruitment of at least 64 patients would lead to at least 50 evaluable patients; for a sample size of 25 patients in each dosing regimen, and assuming that the standard deviation (SD) of the log-transformed data is 0.650 [8] , an increased daily exposure of at least 45% would be necessary to obtain a 95% confidence interval (CI) that does not include 1.00 (i.e., statistically significant). Analyses of PK parameters were performed for the overall population and for age subgroups <2 years and ≥2 years. Statistical analyses of PK parameters were performed on the PK set, which included patients who received at least one dose of study drug, and provided at least five of the six blood samples (including the predose and the 8 h or 12 h postdose samples) and who did not violate the protocol in a way that might affect the evaluation of the main PK endpoint. The PK parameters were determined using a noncompartmental analysis using the Phoenix 64 6.3 software package (Certara L.P., St Louis, MO, USA) on the basis of scheduled time points if there was not more than 5% deviation from the actual ones. AUC 0-24C was calculated as a multiple of the exposure over a dosing interval (AUC) (3 × AUC and 2 × AUC for t.i.d. and b.i.d., respectively). AUC 0-24 and C max were corrected to the target dose of 2 mg kg -1 bosentan (AUC 0-24C and C maxC ) by dividing these values by the actual dose received and multiplying by 2. All AUC and C max values were assumed to be log-normally distributed. The ratios of geometric means of AUC 0-24C and C maxC of bosentan were calculated [test treatment (t.i.d.) : reference treatment (b.i.d.)] and a linear fixed-effects model, with dosing regimen as fixed effect, was used to estimate the 95% CIs. Geometric mean ratios (90% CI) of the metabolite to bosentan AUC 0-24C values were also calculated. The influence of baseline characteristics (WHO FC, body weight, gender, and age at study entry) on AUC 0-24C was assessed in post hoc sensitivity analyses using the linear fixed-effects model to produce baseline covariate-adjusted geometric mean ratios. One interim safety analysis was planned for the study, to identify the need for any dose change. There were no changes in the planned dosing due to this analysis. Safety data were analysed descriptively for the all-treated set, which included all randomized patients who received at least one dose of study drug. AEs and SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 16.0. Upper respiratory tract infection AEs were analysed based on Actelion internal MedDRA queries (nasopharyngitis, influenza, laryngitis, pharyngitis, tonsillitis, bacterial upper respiratory tract infection, viral pharyngitis, and viral rhinitis). Statistical Analysis System (SAS) software, version 9.3 (SAS Institute, Cary, NC, USA) was used for all statistical analyses.
Results
Patient characteristics
In FUTURE-3, 64 patients were randomized to bosentan 2 mg kg there was high interindividual variability in AUC 0-24C for both dosing regimens ( Figure S1 ). The geometric mean ratio (95% CI) was 0.85 (0.61, 1.20) and as the CI between the two dose groups included 1.00, no statistically significant difference could be demonstrated, suggesting that AUC 0-24C was comparable between the two regimens.
In the overall population, the geometric mean (95% CI) for C maxC of bosentan in patients who were dosed 2 mg kg showed high variability and included 1.00, indicating that C maxC was also comparable for both dosing regimens ( Table 2 ). The PK profiles of bosentan for both dosing regimens were characterized by rapid absorption, with a median t max of 3 h Table 2 ). Post hoc sensitivity analyses were performed to explore the influence of specific baseline covariates on AUC 0-24C and C maxC between the two dosing regimens. After adjusting for these covariates, the results were consistent with the unadjusted analyses ( Table 3) .
The metabolite to parent AUC 0-24C ratios for the 2 mg kg (Table 4) .
PK parameters by age group
Overall, PK parameters for b.i.d. and t.i.d. dosing were comparable in both age groups, as indicated by the 95% CI of the geometric mean of AUC 0-24C and C maxC , which largely overlapped for both dosing regimens in both age groups ( Table 2 ). The median t max was identical (3 h) for patients ≥2 years for both dosing regimens. In patients <2 years, the median t max occurred later for t.i.d. dosing (4 h) compared with b.i.d. dosing (3 h). The dosing regimen had no effect on the metabolite to parent AUC 0-24C ratios of Ro 47-8634, Ro 48-5033, or Ro 64-1056 across the age groups (Table 4) . PK parameters of bosentan and the metabolite to bosentan AUC 0-24C ratio in patients <2 years were consistent with those in patients ≥2 years ( Table 2, Table 4 ).
Safety and tolerability
In the overall population, the proportions of patients who experienced ≥1 AE were similar in the b.i. One patient with a congenital diaphragmatic hernia, already on chronic bosentan therapy, did not meet the aetiology inclusion criteria and was erroneously included in the study. The condition of the patient was not expected to affect the safety profile and therefore the patient remained in the study. Furthermore, no impact on the bosentan PK was expected as a result of this condition. 
Figure 2
Arithmetic mean dose-corrected plasma concentration (± standard deviation) vs. time profiles of bosentan on a linear and semi-logarithmic scale. Overall age group; PK set. b.i.d., twice daily; PK, pharmacokinetic; t.i.d., three times daily PK set. AUC 0-24C, area under the concentration-time curve from 0 to 24 h; b.i.d., twice daily; CI, confidence interval; C maxC , maximum plasma concentration; t max , time to maximum plasma concentration; PK, pharmacokinetic; t.i.d., three times daily Table 3 Geometric mean ratios between treatment groups for bosentan pharmacokinetic parameters, with and without adjustment for baseline covariates patient was part of the group ≥2 years. As for the overall population, this exposure value would not have affected the mean calculated for the 19 patients in the PK set. No specific safety issues were noted for this patient.
Discussion
In the present study, the PK and safety profile of an oral paediatric formulation of bosentan were compared following 2 mg kg 24C or C maxC between the two dosing regimens. Other PK endpoints (t max for bosentan and metabolite to bosentan exposure ratios) were also comparable between the dosing regimens, with the latter indicating that the dosing regimen did not influence the extent of metabolism of bosentan.
There was no effect of dosing regimen on the PK parameters of bosentan or the metabolite to parent exposure ratios across the age groups (<2 years and ≥2 years), and PK parameters in patients <2 years were consistent with those in patients ≥2 years. Table 5 Summary of adverse events, serious adverse events and adverse events leading to discontinuation Patients with ≥1 AE leading to treatment discontinuation, n (%)
No. of AEs leading to treatment discontinuation 
FUTURE-3: investigating the dosing of bosentan in paediatric patients
Previous studies have demonstrated that bosentan plasma concentrations in paediatrics are lower than those in adult PAH patients, both with the adult film-coated [9] and the paediatric dispersible formulation tablets [8] . FUTURE-1 showed that increasing the dose of bosentan above 2 mg kg -1 did not increase exposure in paediatric PAH patients in a b.i.d. regimen [8] . Therefore, the t.i.d. dosing regimen was explored in the present study. The data from FUTURE-3 show that -across the paediatric age groups -dosing with bosentan more frequently than twice daily is unlikely to result in increased exposure. A small decrease in exposure was seen with t.i.d. dosing, although this was not considered to be clinically relevant and, overall, the exposure after both t.i.d. and b.i.d. dosing was similar to that observed with bosentan 2 mg kg -1 or 4 mg kg -1 b.i.d. in previous paediatric studies [8, 9] . The median t max for both dosing regimens in the study was also similar to values observed previously in healthy adults [17, 24] and paediatric populations [8, 9] . The results of the present study support those previously seen in FUTURE-1, where it was suggested that paediatric PAH patients reach a bosentan exposure plateau at a lower dose than adults [8] . One possible explanation for this could be the smaller intestinal surface area and/or different absorption characteristics in paediatric patients [8] . In addition, in BREATHE-3, paediatric patients experienced auto-induction of the CYP3A4 and 2C9 enzymes following bosentan administration, similarly to adults [9] . It is not known if increasing the dosing frequency may have had an impact on the level of auto-induction seen in paediatrics, and whether this affected the exposure to bosentan after t.i.d. dosing. In adult patients, it is usual practice for safety reasons to initiate bosentan at 62.5 mg b.i.d. and increase to the maintenance dose of 125 mg b.i.d. after 4 weeks [12] . However, this is not required in paediatric patients as children have a lower exposure to bosentan compared with adults and therefore already have an adequate safety margin. Thus, in the present study, no dose increase was performed, in line with the current prescribing information for bosentan in paediatric patients [12] . In previous studies, 2 mg kg -1 b.i.d. bosentan has been shown to be effective in improving haemodynamics in adults [13] [14] [15] and children [9] , and its long-term safety profile has been assessed [6] . The present study provided no indication that the dosing recommendation should be changed, and 2 mg kg
remains the recommended dosing regimen for bosentan in paediatric PAH patients. Bosentan induces CYP3A4 and CYP2C9; these isozymes catalyse the formation of the three bosentan metabolites [12] . PK parameters of bosentan and its metabolite to parent exposure ratio in patients <2 years were consistent with those in patients ≥2 years. These data indicate that the enzyme activity levels are similar in both age groups. This is an important finding as this was the first paediatric study of bosentan to investigate PK in a population <2 years of age. Although ERAs, PDE-5 inhibitors and prostanoids are all used for the treatment of paediatric PAH and have improved outcomes [25] , the evidence base for their use in paediatric patients <2 years is limited [7-9, 25, 26] .
The majority of AEs were those that would be expected within a paediatric population (e.g. respiratory tract infections) [6] , or were consistent with the known safety profile of bosentan in paediatrics [8] . The safety profile showed no clinically relevant differences between t.i.d. or b.i.d. dosing regimens. FUTURE-3 provided important safety data for bosentan in this group of paediatric PAH patients and there were no new safety risks identified in patients aged 3 months to <2 years.
Limitations of the study included a small sample size of patients below 2 years, which reflects the challenges in recruiting for paediatric PAH studies due to the rare and heterogeneous nature of paediatric PAH [7, 10] . In addition, no placebo or active comparator was used, which may have been a limitation for the safety analysis of bosentan. However, the use of placebo was not considered appropriate due to the widespread use of bosentan and/or other PAH-specific medications in the paediatric PAH population. Although the target dose of bosentan was 2 mg kg -1 , the smallest dose unit was 8 mg (a quarter of a tablet). It was therefore not possible to achieve the exact target dose in all patients. This imprecision could have affected the PK parameters to a small extent, particularly for children with low body weights. Dose-corrected values were used during the analysis, to control for this imprecision.
Overall, there appeared to be no difference in daily exposure, and no clinically relevant differences in safety, when increasing the frequency of bosentan dosing from 2 mg kg -1 b.i.d. to 2 mg kg -1 t.i.d. In addition, the PK of bosentan in patients <2 years of age were consistent with those in patients ≥2 years. Therefore, the present study provided no indication that the dosing recommendation should be changed, and it is concluded that 2 mg kg -1 b.i.d.
remains the recommended dosing regimen for bosentan in paediatric PAH patients. 
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